Edwards Lifesciences Corporation
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B | $823.4M | $1.05B | $722.2M |
| Depreciation & Amortization | $156.6M | $155.2M | $144.9M | $139.6M | $134.8M | $107.2M | $89.3M | $77.4M |
| Depreciation | $148.2M | $137.6M | $119.9M | $114.5M | $127.0M | $101.8M | $84.7M | $74.9M |
| Amortization | $8.4M | $5.6M | $2.2M | $2.3M | $7.7M | $5.4M | $4.6M | $2.5M |
| Stock-Based Compensation | $158.1M | $162.3M | $139.4M | $126.8M | $109.3M | $92.6M | $81.3M | $71.0M |
| Net Cash from Operating Activities | $1.60B | $542.3M | $895.8M | $1.22B | $1.73B | $1.05B | $1.18B | $926.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $260.2M | $252.4M | $253.0M | $244.6M | $325.8M | $407.0M | $254.4M | $238.7M |
| Business Acquisitions | — | — | — | — | $0 | $0 | $100.2M | $0 |
| Net Cash from Investing Activities | $-712.9M | $2.31B | $173.8M | $252.3M | $-1.72B | $-531.1M | $-595.8M | $76.7M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $893.4M | $1.16B | $879.6M | $1.73B | $512.8M | $625.4M | $263.3M | $795.5M |
| Net Cash from Financing Activities | $-956.8M | $-983.0M | $-711.0M | $-1.58B | $-356.3M | $-486.9M | $-115.6M | $-1.10B |
| Net Change in Cash | $-119.3M | $1.91B | $375.4M | $-94.8M | $-332.8M | $15.8M | $468.5M | $-104.2M |
| Free Cash Flow | $1.34B | $289.9M | $642.8M | $973.6M | $1.41B | $647.3M | $928.5M | $688.0M |